Amgen and Sandoz face off again over biosimilars
03-03-2016
Sandoz too quick off the mark in Amgen suit: US court
09-12-2014
13-08-2019
Pavel Kapysh / Shutterstock.com
Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel (etanercept), effectively blocking the launch of Sandoz’s biosimilar version.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sandoz, Amgen, Enbrel, biosimilars, patent validity, FDA, Erelzi, arthritis, Roche